Imunon, INC Form 4 insider transactions

Christine A. Pellizzari, a Director at Imunon, Inc., acquired 5,557 shares of common stock on May 22, 2026, valued at $2.20 per share.

Imunon, Inc. Director James E. Dentzer reports acquisition of 11,148 shares of common stock.

Donald P. Braun, a Director at Imunon, Inc., acquired 5,011 shares of common stock on May 22, 2026, as compensation for board fees.

Imunon, Inc. reports a Form 4 filing detailing the acquisition of common stock by Director Frederick J. Fritz as compensation for board services.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 1,491 shares of common stock on May 22, 2026, as part of her compensation.

Imunon, Inc. President and CEO Stacy Lindborg was granted 56,187 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc.'s CFO, Kimberly Bragg, was granted 9,050 stock options with an exercise price of $3.95, vesting over two years.

Imunon's Chief Scientific Officer, Khursheed Anwer, was granted 15,736 stock options with an exercise price of $3.95, aligning executive incentives with shareholder value.

Imunon, Inc. Director Frederick J. Fritz acquired 5,892 stock options with an exercise price of $3.95, vesting over two years.

Imunon's Chief Medical Officer, Douglas Vincent Faller, was granted 12,667 stock options with an exercise price of $3.95.

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, was granted 8,251 stock options with an exercise price of $3.95.

Imunon, Inc. director Christine A. Pellizzari was granted 4,827 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc. Director Donald P. Braun was granted 5,881 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc. Director James E. Dentzer was granted 4,405 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc.'s Executive Chairman, Michael H. Tardugno, acquired 43,821 stock options with an exercise price of $3.95.

Imunon, Inc. CEO Stacy Lindborg acquired 1,667 shares of common stock through the vesting of restricted stock, increasing her direct beneficial ownership.

Imunon, Inc. Director James E. Dentzer acquired common stock and stock options on August 4, 2025, following a 1-for-15 reverse stock split effected on July 25, 2025.

Imunon Director Christine Pellizzari acquired 2,248 shares of common stock and 250 stock options, partly in lieu of cash board fees, following a recent 1-for-15 reverse stock split.

Imunon, Inc. Director Donald P. Braun acquired 2,040 shares of common stock and 250 stock options as compensation, following a 1-for-15 reverse stock split.

Imunon, Inc. director Frederick J. Fritz acquired common stock and stock options as compensation following a 1-for-15 reverse stock split.

Imunon's Chief Scientific Officer, Khursheed Anwer, acquired 1,667 stock options with an exercise price of $9.2, following a recent 1-for-15 reverse stock split.

CFO Kimberly Bragg acquired stock options in Imunon, Inc. on August 4, 2025.

Imunon's General Counsel and Corporate Secretary, Susan Eylward, was granted 417 stock options with an exercise price of $9.20, adjusted for a recent 1-for-15 reverse stock split.

Imunon, Inc.'s Executive Chairman, Michael H. Tardugno, was granted 1,667 stock options with an exercise price of $9.2, following a 1-for-15 reverse stock split.

Imunon, Inc. CEO and Director Stacy Lindborg was granted 5,000 stock options with a $9.2 exercise price, vesting over two years.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., was granted stock options for 25,000 shares on March 14, 2025, according to a Form 4 filing.

Director Frederick J. Fritz of Imunon, Inc. was granted stock options to purchase 3,750 shares of common stock at an exercise price of $0.8651 on March 14, 2025.

Director Donald P. Braun reports acquisition of stock options in Imunon, Inc.

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., acquired stock options on March 14, 2025.

James E. Dentzer, a director of Imunon, Inc., was granted stock options to purchase 3,750 shares of common stock at an exercise price of $0.8651 on March 14, 2025.